From Lab to Clinic – Clinicians Perspective Working on the Frontline

Time: 10:15 am
day: Post Conference Day


• The common causes of genetic hearing loss may require the attention of the gene therapy industry. Get the number of cases right – rare diseases are rare, consider going for common gene, may be hard but worth it in the long run
• The proof of gene therapy is in the outcomes. This has to be better than what is being offered at the moment such as hearing aids for moderate hearing losses and cochlear implants for severe to profound hearing losses
• The long-term sustained ability is important, the inner ear therapeutic development was needed to look at the world of cancer and long-term survival. The same rule needs to apply inner ear therapies such as hearing preservation on medium to long-term